To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
RXi Pharmas Gene Therapy Gets Patent Boost
This patent includes the Company's lead clinical candidate, RXI-109, which is currently being evaluated in multiple clinical trials to reduce scar formation in the skin and eye. The patent, once issued, will not expire until 2031.
"We are pleased to have be granted this Notice of Allowance from the USPTO," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "This patent protection for our novel self-delivering RNAi technology further strengthens our position to generate business and commercial development opportunities in the areas of dermal and ocular scarring as well as other fibrotic indications, such as liver fibrosis".
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
